Researcher CONNECT

Advances in our understanding of cancer immunology and the mechanisms by which cancer immunotherapies exert their effects have translated into increasingly positive patient outcomes.

The recent successes of immunotherapeutics, particularly immune checkpoint inhibitors, have served to demonstrate the power and potential of immune-based treatment strategies. Now there is a need to build upon what we have learned in order to effectively treat more patients with cancer.

Cancer Immunotherapy CONNECT, powered by SITC is your hub for live and online educational opportunities. This website provides access to all of the latest data in the field of tumor immunology and cancer immunotherapy. Connect to other researchers in our online Community and submit your manuscript to JITC to help drive progress.

Discussions

  • As you note, there are now many options for refractory metastatic RCC. They each have unique features which may make them more or less suitable for individual patients. I tend to use...

    2 people recommend this.
  • Although there is not clear evidence on sequencing or how to choose the best option for second line therapy in RCC. What do you think is important to consider, in terms of patient profile,...

    2 people recommend this.
  • Seb, The problem with reporting the conventional median overall survival is that it doesn't capture the tail of the curve, which is the place that each and every patient wants to end...

    2 people recommend this.

Resources

Jan 16, 2017 2:30 PM
This program provides a snapshot of current research related to the identification of tumor antigens, characterization and isolation of specific T-cells for therapy, and discovery of neo-antigens all aimed at enabling the next generation of immunotherapies. Specific approaches driving immunotherapy...
Jan 16, 2017 12:15 PM
The 2015 SITC Primer on Tumor Immunology and Cancer Immunotherapy™ provided a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. The presentations gave an overview of several general immunology and cancer immunotherapy...
Jan 11, 2017 3:57 PM
From the 30th Anniversary Annual Meeting in National Harbor, MD on November 7, 2015. Presenter: Jedd D. Wolchok, MD, PhD - Memorial Sloan Kettering Cancer Center
Jan 11, 2017 3:40 PM
From the 2015 Advance in Cancer Immunotherapy™ in Washington, DC. Presenter: Mario Sznol, MD- Yale School of Medicine.

Events


Featured Videos

NSCLC Immunotherapy - Advancing Hope™

Launched in July of 2016, SITC presents the newest in a series of videos focusing on immunotherapy for NSCLC patients, the NSCLC Immunotherapy: Advancing HopeTM video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some of the available FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials.

SITC – Leading the Cancer Immunotherapy Evolution

For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.